» Articles » PMID: 18303985

Deviance-elicited Changes in Event-related Potentials Are Attenuated by Ketamine in Mice

Overview
Journal J Cogn Neurosci
Specialty Neurology
Date 2008 Feb 29
PMID 18303985
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Background: People with schizophrenia exhibit reduced ability to detect change in the auditory environment, which has been linked to abnormalities in N-methyl-D-aspartate (NMDA) receptor-mediated glutamate neurotransmission. This ability to detect changes in stimulus qualities can be measured with electroencephalography using auditory event-related potentials (ERPs). For example, reductions in the N100 and mismatch negativity (MMN), in response to pitch deviance, have been proposed as endophenotypes of schizophrenia. This study examines a novel rodent model of impaired pitch deviance detection in mice using the NMDA receptor antagonist ketamine.

Methods: ERPs were recorded from unanesthetized mice during a pitch deviance paradigm prior to and following ketamine administration. First, N40 amplitude was evaluated using stimuli between 4 and 10 kHz to assess the amplitude of responses across the frequency range used. The amplitude and latency of the N40 were analyzed following standard (7 kHz) and deviant (5-9 kHz) stimuli. Additionally, we examined which portions of the ERP are selectively altered by pitch deviance to define possible regions for the mouse MMN.

Results: Mice displayed increased N40 amplitude that was followed by a later negative component between 50 and 75 msec in response to deviant stimuli. Both the increased N40 and the late N40 negativity were attenuated by ketamine. Ketamine increased N40 latency for both standard and deviant stimuli alike.

Conclusions: The mouse N40 and a subsequent temporal region have deviance response properties similar to the human N100 and, possibly, MMN. Deviance responses were abolished by ketamine, suggesting that ketamine-induced changes in mice mimic deviance detection deficits in schizophrenia.

Citing Articles

Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in Schizophrenia.

Javitt D Adv Neurobiol. 2024; 40:411-451.

PMID: 39562453 DOI: 10.1007/978-3-031-69491-2_15.


Neurophysiological Models in Individuals at Clinical High Risk for Psychosis: Using Translational EEG Paradigms to Forecast Psychosis Risk and Resilience.

Hamilton H, Mathalon D Adv Neurobiol. 2024; 40:385-410.

PMID: 39562452 DOI: 10.1007/978-3-031-69491-2_14.


The Use of Event-Related Potentials in the Study of Schizophrenia: An Overview.

Crown L, Featherstone R, Sobell J, Parekh K, Siegel S Adv Neurobiol. 2024; 40:285-319.

PMID: 39562449 DOI: 10.1007/978-3-031-69491-2_11.


Neural substrates of cognitive impairment in a NMDAR hypofunction mouse model of schizophrenia and partial rescue by risperidone.

Delgado-Sallent C, Gener T, Nebot P, Lopez-Cabezon C, Puig M Front Cell Neurosci. 2023; 17:1152248.

PMID: 37066076 PMC: 10104169. DOI: 10.3389/fncel.2023.1152248.


An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.

Choueiry J, Blais C, Shah D, Smith D, Fisher D, Labelle A J Psychopharmacol. 2023; 37(4):381-395.

PMID: 36927273 PMC: 10101183. DOI: 10.1177/02698811231158903.